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There exists this stupendous beauty called compassion 
                                            And therefore, the world exists. 
                                         -Poet Thiruvalluvar
  
ABSTRACT 
Type 2 immune responses are characterized by the production of cytokines IL-4, IL-5 and 
IL-13. They are known to have crucial physiological and pathophysiological functions in the 
body. Data from recent studies indicate their importance in the containment and clearance of 
helminth infections. They are induced to generate rapid response against helminth infections 
even before the elicitation of specific adaptive responses. On the other hand, Th2 responses 
are also involved in the promotion of inflammatory conditions such as allergy and asthma. 
Studies from the past have probed the mounting of type 2 immune responses and Th2 
cytokine production by innate immune cells. In this thesis, we set out to study two innate 
cells, which are considered to be one of the key drivers of allergic conditions – mast cells and 
group 2 innate lymphoid cells.  
In paper I, an optimized protocol to efficiently isolate mast cells from human lung tissue 
with high yield and cell viability is described. Mast cells are heterogeneous, tissue-resident 
inflammatory cells characterized by the expression of high-affinity IgE receptor, FcεRI, and 
CD117/KIT, the receptor for stem cell factor (SCF). The isolation of mast cells was 
performed by a sequential combination of washing, enzymatic digestion, mechanical 
disruption and Percol centrifugation (WEMP). The yield from WEMP protocol was 
significantly high when compared to the conventional enzyme-based method. The isolated 
cells were further used for flow cytometry-based characterization studies and single cell RNA 
sequencing.  
Paper II is a study of human lung mast cells at the single cell level using RNA sequencing. 
The classic marker expression by mast cells revealed the integrity of the sort and the 
sequencing reactions. Following this, analyses of sequencing data was performed to depict 
highly variable genes, highly abundant genes and the presence of subpopulation. Preliminary 
data displayed homogeneity within the sorted population of the isolated lung mast cells with 
no clear subpopulations.  
In paper III, the fundamental aim was to determine the effects of prostaglandin D2 on ILC2. 
ILC2 play critical roles in the initiation and promotion of type 2 immune responses. The 
results indicated the constitutive expression of prostaglandin D2 synthase by ILC2 and the 
endogenous PGD2 production was involved in the activation of ILC2 through CRTH2 
receptors in a para/autocrine fashion. 
In paper IV, the study was designed to elucidate the effect of PGE2 on ILC2. ILC2 were 
isolated, cultured and expanded under different treatment conditions to study the effect. PGE2 
was found to have suppressive effect on GATA3 and IL-2 receptor (CD25) expression and 
cytokine production by ILC2. The suppressive effects were mediated by EP2 and EP4 
receptors. The use of EP2 and EP4 agonists can therefore serve as potential therapeutic target 
in controlling ILC2 mediated inflammation.  
In conclusion, the results from our studies add to the already known information about 
initiation, maintenance and regulation of type 2 immune responses. They serve as basis for 
future mast cell-ILC2 interaction studies that could provide potential insights into their 
contribution in allergic and other TH2-driven conditions.   
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1 INTRODUCTION 
Our immune system is an extensively evolved phenomenal defence system made up of a 
humongous array of cells primarily dedicated to protect our body from invading pathogens. 
They can not only distinguish foreign from its own but also can recognize the subtle 
differences between the foreign molecules and therefore can display remarkable specificity. 
Traditionally, immune responses to pathogens are broadly divided into two main categories 
- innate and adaptive. The very first line of defence upon pathogen encounter occurs in a non-
specific, yet effective manner by the recruitment of a number of innate cell types. This type 
of response is important for the rapid initial action to pathogen entry and exists from the birth. 
In adaptive immune responses, the initial recognition of the pathogen is relatively delayed 
yet is followed by the mounting of an appropriate effector response specific to the pathogen 
in order to eliminate or neutralize them. Adaptive arm of the immune system mainly 
constitutes B and T cells, which can respond in a highly specific way. The subsequent 
exposure to the same antigen induces a more accelerated memory response by B and T cells. 
The innate arm, on the other hand, is comprised of rapidly responding cells such as 
macrophages, neutrophils, dendritic cells that are readily present at the infection site and 
actively participate in the control and clearance of infection.  
1.1 TYPE 2 IMMUNE RESPONSES 
 
Type 2 innate immune responses are characterized by the production of type 2 cytokines IL-
4, IL-5, IL-9 and IL-13 by the recruitment and activation of TH2 cells, eosinophils, mast 
cells, ILC2 and basophils. Protective aspect of type 2 immunity lies majorly in orchestrating 
resistance against parasitic infections at the cutaneous and mucosal surfaces [1, 2]. Recent 
evidences suggest their protective roles in autoimmune diseases by suppressing type 1 driven 
tissue damage, inflammation and fibrosis [3-6]. Contrastingly, they play critical roles in the 
promotion of allergic inflammatory conditions like asthma, atopic dermatitis and anaphylaxis 
[7, 8].  
In response to allergens and helminths, epithelial cells produce TSLP, IL-25 and IL-33, which 
serve as the major inducers of type 2 immune response [9-11]. TSLP is identified as a potent 
Th2 activating cytokine that causes CD4+ T cell differentiation by the induction of dendritic 
cells. These TSLP-activated dendritic cells in turn produce Th2 attracting chemokines 
CCL17, CCL22, CCL24 [12, 13] 
In mice, IL-25 promotes TH2 response by bringing about eosinophilia and IgE production 
leading to type 2 cytokine release especially in the lung. This type of IL-25 induced Th2 
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response advocates inflammatory conditions in the lung [14, 15]. IL-33-activated basophils 
build up type 2 responses by generating IL-4, IL-5, IL-6 and IL-13. IL-33 administration in 
mice caused the IgE release, hyperplasia of goblet cells and eosinophilia [16-18]. 
The cytokine mediated effects of these responses can be both specific and non-specific. 
Recruitment and activation of innate cells by IL-25 and IL-33 caused the production of IL-5 
and IL-13. This effect was shown to occur entirely independent of B and T cells [14, 19, 20]. 
As mentioned previously, mast cells and basophils produce TH2 cytokines upon activation. 
In addition to this, NKT cells and ILC2 have IL-25 receptor (IL25R) and therefore can be 
activated by IL-25 that ultimately causes IL-13 release [21, 22]. In addition to suppression of 
TH1 driven inflammation as discussed above, type 2 cytokines such as IL-4 and IL-13 have 
found to be driving macrophages to promote tissue repair and regeneration following 
inflammation [23]. Increase in Th2 cytokine levels in response to chronic helminth infection 
often result in fibrotic lesions. Initial fibrosis resulting from worm egg storage in liver, lung 
and gut is highly altered by IL-4, IL-5 and IL-13 in addition to TH2 activated eosinophils 
and macrophages causing type 2 fibrotic condition [24, 25]. Such contrasting roles of type 2 
immunity in health and diseases explain the persistent efforts made in the medical field to 
carefully target their pro inflammatory roles without sacrificing their effective functions in 
health. 
1.1.1 Type 2 immunity in allergic inflammation 
Repetitive exposure to allergen leads to chronic inflammatory condition. Long term 
persistence of inflammation leads to asthma characterized by airflow obstruction, hyper 
responsiveness, mucus accumulation and airway remodelling. Asthma is recognized as a type 
2 inflammatory disorder characterized by type 2 cytokine-driven inflammation [10]. IL-4 
induces the basophil activation and IgE-dependent mast cell degranulation leading to the 
release of their mediators. IL-5 and IL-9 autonomously induce mast cell hyperplasia and 
eosinophilia. IL-13, on the other hand, promotes the hyperplasia of goblet cells during mucus 
production and airway hyper responsiveness in asthma. Elementary mouse models of asthma 
revealed the crucial roles of TH2 cells, mast cells and eosinophils in driving the disease [26, 
27]. 
IL-33 is a potent activator of IL-5 and IL-13-producing ILC2, which are important during 
initial inflammatory phases. They also create in interface between IL-33 and eosinophils to 
facilitate eosinophilic inflammation as observed in ILC-deficient mice [28-30]. TSLP-
deficient asthma mice models demonstrated resistance to airway hyper responsiveness 
indicating their allergy promotion roles [31]. The detailed pro inflammatory roles of mast 
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cells and ILC2 during the latent and chronic phase of allergic inflammation has been 
discussed in the following sections of this thesis.  
1.2 MAST CELLS 
Mast cells have remained inexplicable for over a century since they were first described as 
’mastzellen’ by Paul Enrich in the year 1878. Persistent research carried out in the field has 
helped unravel their characteristics and functions over the years.  
1.2.1 Mast cells  
The progenitors of mast cells originate from the pluripotent hematopoietic cells of the bone 
marrow and circulate in blood at low frequencies. The progenitors migrate to tissues where 
they mature under the influence of epithelial and mesenchymal-derived growth factors such 
as SCF and become exclusively tissue resident [32, 33]. These non-proliferative mature tissue 
resident cells are well-characterized by their surface expression of classic markers such as 
the high affinity immunoglobulin E (IgE) receptor, FcεRI, stem cell factor receptor CD117 
[34]. The secretion of various mediators and cytokines by mast cells has been shown to play 
significant roles in inflammatory and allergic responses. Mast cells are found throughout the 
body, particularly in connective tissues. They contribute to body’s first line of defence by 
their presence particularly in tissues in close contact with the environment; i.e., skin, lung 
and the gastrointestinal tract [35, 36]. 
1.2.2 Heterogeneity and activation 
The heterogeneous nature of mast cells is due to the variation displayed by them in terms of 
granularity, protease content, responsiveness to agents and mediator release. Based on the 
above factors, mast cells are compartmentalized in different parts of the same tissue such as 
the lung. Mast cells are classically divided into two main subsets based on their protease 
content – MCT and MCTC. Tryptase positive cells, often found in lung parenchyma and 
mucosal tissues, are classified as MCT. Mast cells that express chymase, carboxypeptidase 
and cathepsin G in addition to tryptase are called MCTC, predominantly found in connective 
tissues such as the skin [37]. A recent study described the presence of a new mast cell subset 
in airway epithelium of asthmatic patients expressing tryptase and carboxypeptidase A3, but 
not chymase[38]. Detailed description and characterization of such mast cell subsets are 
crucial in order to understand their role in homeostatic and disease conditions. Researching 
mast cells in such depth is made possible by recent advancements in the field that help us 
study them at single cell resolution.  
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As described above, mast cells are the storehouses of numerous granules such as histamine, 
serine proteases, chymase, heparin, and cytokines [39]. The classic and well-defined mast 
cell activation occurs through cross-linking of two IgE-molecules bound to high-affinity IgE 
receptors cross-linking, an activation that is more relevant in allergic responses. Initial 
exposure to the allergen causes the binding of IgE to the FcεRI receptor on the mast cells. 
Subsequent allergen exposure results in the cross linkage of FcεRI resulting in the initiation 
of signalling cascade. The proceeding series of events ultimately lead to mast cell 
degranulation – release of their cellular contents.  Upon their activation, mast cells also de 
novo synthesize and release inflammatory cytokines and lipid mediators that mediates 
various effects. [40].  
 
Figure 1: IgE dependant mast cell activation. 
 
Mast cell activation occurs also through a number of IgE independent pathways. Their 
location proximal to the external environment makes their encounter of pathogen likely and 
therefore their activation through pattern recognition receptors dependent [35]. Products of 
inflammation such as complements, IgG, cytokines, chemokines, adenosine etc. can also 
trigger mast cell activation. Mast cells located at the sensory nerve endings can be activated 
by neurotrophins and neuropeptides suggesting their contribution to neuro-inflammatory 
disorders [41]. Recent studies identified the activation of MCTC by Mas-related G protein-
coupled receptor X2 (MRGPRX2) leading to phospholipase C mediated release of 
cytoplasmic calcium release. [42]. 
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1.2.3 Mast cells in type 2 immune response 
In parasitic infections, antigen specific IgE-dependent mast cell degranulation results in 
release of growth factors like IL-3, IL-4, SCF, IL-9, which aids in regulating gastrointestinal 
permeability and recruitment of immune cell to the infection site. Mast cells play crucial role 
in the regulation of type 2 immune responses to helminth infections. Th2 responses have been 
shown to be inhibited when mice lacking mast cells (KitW/ KitW-v and KitW-Sh) were infected 
with parasitic helminth Heligmosomoides polygyrus bakeri. Apart from antigen specific IgE 
dependent degranulation, mast cells can also be activated in an IgE independent manner in 
response to parasites. During intestinal helminth infections, the secretory products serve as 
ample stimulatory molecules that can be sensed by mast cells through their surface TLRs, 
protease-activating receptors (PARs) and cause their degranulation [43]. The tissue derived 
cytokines IL-33 and TSLP released in response to pathogens and allergens can act on mast 
cells affecting their functions [44-46]. 
1.2.4 Physiological role of mast cells 
The widespread distribution particularly at the interface between host and external 
environment put mast cells in a privileged position to take part in biological actions and be 
one of the first responders to external stimuli [47]. Mast cells contribute to the body’s innate 
immune response by recognizing and interacting with pathogens, antigens and toxins.  
Pattern recognition receptors like TLR expressed by mast cells facilitate the direct binding 
of pathogens to them ultimately causing mast cell degranulation [48]. The release of 
inflammatory mediators thereby aids the control and clearance of pathogens. Release of such 
mast cell mediators upon TLR binding depends on the ligand and the receptor [49]. Classic 
examples of such reactions include the recognition and binding of TLR2 by bacterial 
peptidoglycan, TLR4 by LPS [50, 51].  
Mast cells also react to viral infection by producing interleukins IL-1, IL-6 and chemokine 
ligands like CCL3, CCL4, CCL8 [52, 53]. 
Number of mediators released during mast cell activation induces various physiological and 
immunomodulatory functions in endothelial, nervous and epithelial tissues. Mast cells 
maintain the tissue function and homeostasis through mediators such as histamine, tryptase 
and VEGF [54]. Mast cell tryptase has been shown to activate protease-activating receptor 2, 
which inhibits differentiation of osteoclasts [55]. On the other hand, mast cell mediators such 
as platelet activating factor (PAF), leukotrienes, t-plasminogen (tPA), heparin, tryptase are 
released by them in response to tissue injury that regulate fibrinolytic mechanisms thereby 
promoting tissue repair and remodelling [56, 57]. 
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1.2.5 Pathological role of mast cells 
In contrast to their multifunctionality in homeostasis, mast cells have typically been 
associated with pathological conditions such as allergy, asthma, mastocytosis and so on. 
Improper regulation of mast cells causes them to respond to harmless antigens in an 
imprudent manner. Under such circumstances, antigen-specific IgE that are produced by B 
cells bind to the FcεRI receptor on mast cells causing sensitization. Subsequent antigenic 
exposure ultimately results in mast cell degranulation and release of pre-formed and newly 
synthesized mast cell mediators and cytokines. The released pro-inflammatory mast cell 
contents such as histamine, prostaglandins and leukotrienes trigger allergic reactions causing 
symptoms like mucus production, edema and itch [48]. The release of cytokine leads to the 
recruitment and activation of other immune cells like T cells, eosinophils, basophils causing 
persistent chronic inflammation, tissue remodelling and fibrosis that can be observed in 
disorders like asthma [58, 59]. Crohn’s disease is characterized by the chronic inflammation 
of the gastrointestinal tract. Mast cells have shown to contribute to the disease pathology by 
releasing IL-16. The mast cell produced IL-16 causes the recruitment of circulating T 
lymphocytes to the inflammatory site [60]. In mastocytosis, a primary mast cell-driver 
disease, the clonal accumulation of mast cells is caused by a c-KIT activating mutations that 
causes mast cell accumulation in bone marrow, GI tract, skin and other organs [61]. 
Phenotypic modifications of mast cells under the influence of micro environmental changes 
in the tissue, e.g., during inflammation, determine their roles in health and pathophysiological 
conditions. Such multifunctionality brings about a need to study these cells in depth. In this 
thesis, we have described two such studies – a protocol for the effective isolation of human 
lung mast cells and their detailed characterization using single cell RNA sequencing 
platform. 
1.3 INNATE LYMPHOID CELLS 
Innate lymphoid cells are a novel heterogeneous family of cells consisting of 3 main subsets 
- group 1 (ILC1), group 2 (ILC2), and group 3 (ILC3) [62, 63]. They play roles in various 
bacterial, fungal, viral and parasitic infections [64]. Their improper regulation causes the 
worsening of chronic inflammatory conditions such as allergy, asthma, COPD, IBD etc [65, 
66]. ILCs also have roles in driving certain cancers and autoimmune disorders [67]. The 
homeostatic and inflammatory roles of ILCs are being extensively studied for the better 
understanding of their roles.  
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1.3.1 Group 2 innate lymphoid cells  
Group 2 innate lymphoid cells (ILC2) originate from the common lymphoid progenitor of 
bone marrow and become committed to ILC2 lineage. The maturation, maintenance and 
survival of ILC2 mainly rely on the transcription factor GATA3 and RORa expression. 
Genetic knockout studies in mice proved GATA3 to be a crucial transcription factor in the 
ILC2 development and regulation. Mature ILC2s are characterized by their predominant 
expression of GATA3 and production of type 2 cytokines IL-4, IL-5, IL-9 and IL-13 [68-70]. 
These cells lack antigenic receptor expression on their surface unlike B and T cells. Owing 
to this reason, ILC2 confer immune responses in a non-specific manner making them a strong 
part of the innate immune family [71]. ILC2 are highly responsive to and activated by IL-33, 
IL-25 and TSLP [72]. CRTH2 a receptor for prostaglandin D2 (PGD2) is expressed in human 
ILC2 and can activate them upon CRTH2-PGD2 binding [73].  
 
Figure 2: Activation of ILC2 
 
The two major classes of ILC2 are natural ILC2 (nILC2) and inflammatory ILC2 (iILC2). 
Natural ILC2, as the name suggests, mostly possess functions related to homeostasis [74] and 
respond to IL-33. Recent experiments on the synovial samples of arthritic patients suggest a  
possible IL-9 mediated anti-inflammatory role of ILC2 by restriction of inflammation and 
cell death.  Their close proximity to regulatory T cells at the site of inflammation and their 
abundant IL-9 production were observed in these samples [75]. On the contrary, iILC2 that 
respond to IL-25, has pro-inflammatory roles that promote certain chronic inflammatory 
conditions through their surface expression of KLRG1 and IL25R. These pro inflammatory 
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ILC2 are highly responsive to chemotactic signals and migrate between mucosal sites 
promoting cytokine mediated type 2 inflammation [76].  
Recent advancement in the field has enabled the high throughput, in-depth analyses of ILC2 
using RNA-seq, CHIP-seq platforms in order to better understand their transcriptional and 
regulatory network [77, 78]. Heterogeneity in the ILC2 exits because of their interaction with 
the different environmental situations. The gene expression profile and phenotypic variations 
exist from counterbalancing their anti and pro inflammatory roles [79]. The above described 
natural and inflammatory ILC2s are a result of the establishment of such an equilibrium. 
ILC2 subclasses have been identified based on their gene expression - ILC1/2 also expressing 
Gzma, Hopx Epas1 and ILC2/3 expressing Cxcl2, Cxcl3, Arg1 [80].  
1.3.2 ILC2 plasticity 
ILCs are known for their plastic nature, which was first observed in the ILC3 present in gut, 
where they modify their gene expression to transform into ILC1 [81]. ILC2 are able to show 
plasticity by upregulating T-bet in the presence of IL-33 and IL-1β and produce interferon g 
(IFNg) to become ILC1 [66, 82, 83]. Administration of IL-25 in mice resulted in the 
generation of IL-17 producing inflammatory ILC2, a typical ILC3 cytokine, which is in 
addition to their well-defined type 2 cytokine profile [74]. In another notch ligand mediated 
condition, ILC2 upregulate Rorgt and produce IL-17 and IL-13 causing ILC2 to ILC3 
transformation [84]. In addition to the above heterogeneous nature of ILC, recent mice 
studies identified a group of ILC that has regulatory roles through IL10 production [85]. 
1.3.3 Role of ILC2 in type 2 immune responses 
ILC2, as discussed above, performs various pro- and anti-inflammatory roles in the body 
through their predominant production of type 2 cytokines, i.e., IL-4, IL-5, IL-9 and IL-13 
upon activation through IL-25, IL-33 and TSLP. Due to the absence of an antigenic receptor, 
therefore a lack of specificity, they stand unique from the CD4+ Th2 helper cells. ILC2 play 
a role in orchestrating type 2 immune responses such as eosinophilic induction, class 
switching of B cells, expansion of CD4+ T cells, initiation of adaptive immune response.  
ILC2 from the spleen and lymph nodes of mice expressed MHC-II and co-stimulatory 
molecules such as CD80 and CD86. Combined expression of these molecules allowed the 
CD4+ T cell interaction, activation and expansion, which is critical in the clearance of murine 
helminth infection [86]. In humans, ILC2 are found in tonsils, skin, spleen, lymph nodes, 
liver, blood and lungs [87-91]. ILC2 population were assessed in helminth infected children 
in Zimbabwe. Children aged 6-13 had lower ILC2 counts when compared to uninfected 
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cases. While 14-18-year-old groups has higher ILC2 counted in comparison with uninfected 
individuals. These findings suggest an early role of ILC2 in parasitic infection and also in the 
initiation of Th2 immune response [92]. ILC2 are found to be located in proximity to the 
enteric neurons. These neurons are capable of activation and cytokine production of ILC2 by 
interacting through mediators. The vasoactive intestinal peptide (VIP) receptor engagement 
causes the enhancement of type 2 cytokine production by ILC2 [93]. Further ILC2 helps in 
the pathogen clearance and tissue repair in the lung through post viral infection through the 
release of epidermal growth factor amphiregulin, which is predominantly expressed by Th2 
cells [94]. 
Apart from the protective roles, ILC2 critically contribute to the promotion of chronic 
inflammatory condition by means of cytokine production. They are said to be the key drivers 
of type-2 mediated inflammatory diseases like asthma. Intranasal delivery of the ILC2 
activating epithelial cytokines such as IL-25 and IL-33 resulted in the induction of an allergic 
response even in the absence of B and T cells implicating the involvement of ILC2 in the 
promotion of such response [14, 29]. In the absence of T cells, papain induced lung 
inflammation by means of ILC2 suggesting the ability of these cells to stand alone in 
promoting Th2 inflammation [28]. Furthermore, ILC2 are found to be enriched in chronic 
rhinosinusitis and atopic dermatitis patients suggesting their pro-inflammatory roles in other 
sites as well. Skin-residing ILC2, however, are mainly activated by TSLP and remain 
resistant to the action of IL-25 and IL-33 [95]. This observation indicated the variability of 
ILC2 characteristics based on where they reside [96]. Much remains to be studied about 
biology and functions of these fairly new cells. The possibility of these cells to be a potential 
therapeutic target poses the need to study their key anti-inflammatory functions. In this thesis, 
we have probe into the factors involved in the activation and inhibition of ILC2 functions 
that provide new insights in understanding them better.  
1.4 LIPID MEDIATORS 
1.4.1 Arachidonic acid 
Lipid mediators have many essential physiological and pathological functions. They often 
engage in cell proliferation, migration and apoptosis. Arachidonic acid (AA) is a well-studied 
PUFA composed of 20 carbon atoms. Egg, fish, seafood and poultry are some of its abundant 
sources [97, 98]. They are generally found to be fused with the phospholipids in the cell 
cytoplasm. One fourth of phospholipid fatty acids in cells such as mononuclear cells, 
neutrophils, platelets and tissues such as brain, muscle, liver is in the form of AA [99, 100]. 
They help in maintaining selective permeability and integrity of the cell membrane serving 
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as a basic constituent of the cell [101, 102]. They are necessary for general growth and 
development, especially in newborns where they are an important nutrient supplement [103, 
104].  
AA is present adjacent to the endoplasmic reticulum and nuclear membrane of the cell [99]. 
Upon cellular activation, AA is freed from phospholipids by the action of enzyme 
phospholipase A2 (PLA) [105]. The metabolism of the released AA can lead to two main 
pathways – either by the enzyme cyclooxygenase (COX) or by lipoxygenase (LOX). The 
downstream products of these pathways are collectively known as eicosanoids and consist of 
prostaglandins, leukotrienes, thromboxanes and lipoxins. Eicosanoids have various 
biological roles in cell growth, vascular permeabilization, inflammation, blood pressure 
maintenance, platelet aggregation etc. [106]. The generation of prostaglandin G2 (PGG2) 
from the intracellular AA is catalysed by the COX enzymes [107]. Further activation of 
synthases leads to the conversion of PGG2 to PGH2. The downstream metabolites of AA 
encompass inflammatory roles such as immune cell activation, bronchoconstriction and 
vasodilation [108, 109]. 
1.4.2 Prostaglandins & Leukotrienes 
Prostaglandins are found almost throughout the body and have both pro- and anti-
inflammatory effects. Consequent to activation, mast cells release AA metabolites such as 
PGD2 and leukotriene C4 (LTC4) that have significant roles in health and diseases. PGD2 is 
a biologically active lipid that is enzymatically derived from PGH2 by the action of PGD2 
synthase [107]. PGD2 is particularly expressed by mast cells and is a classic mast cell marker. 
CRTH2 and PTGDR are the well-defined receptor for PGD2 [110, 111]. They participate in 
the recruitment of immune cells such as Th2 cells, eosinophils and basophils. They play 
critical role in the development of allergic conditions such as asthma owing to their roles in 
bronchial constriction, vasodilation and mucus production [112].  
The potential effects of PGD2 on ILC2 have been studied extensively in both human samples 
and mouse models [113]. One of their major interaction pathways is via CRTH2, a well-
known surface receptor expressed on human ILC2. Studies have demonstrated that PGD2 can 
induce ILC2 to produce IL-13 through CRTH2 receptor activation [114]. It has also been 
shown that PGD2 induced the production of IL-5 and IL-13 by human skin ILC2 [73]. They 
help in the chemotaxis of human blood ILC2 [115]. Upon treatment of CRTH2 antagonist, 
IgE-activated mast cells were found to have lesser stimulatory effects[73]. Helminth mouse 
models were found to have increased ILC2 accumulation upon PGD2 action [116]. Adding 
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to these, PGD2 is found in considerable amounts in brain and its signalling blockade in krabbe 
mouse models lowered neuro-inflammatory effects [117].  
Unlike pro-inflammatory effects, the role of PGD2 and its distal products in the resolution of 
inflammation is not well studied. LPS induced inflammation in human models causes flu-
like symptoms combined with pyrexia. The PGJ2, a downstream product of PGD2 
metabolism has been shown to have anti-pyretic effects in these models [118]. Undermining 
of inflammation by PGD2 is observed in models of pleuritis, a lung inflammatory condition 
[119]. 
PGE2 is another lipid mediator derived from arachidonic acid. It acts through the binding of 
four different E-type prostanoid receptors such as EP1, EP2, EP3 and EP4. The sensitivity 
and activation pathways of these EP receptors diverge, which explains the pro and anti-
inflammatory roles of PGE2. The protective roles of PGE2 in allergy and asthma is supported 
by recent studies in mouse models [120, 121]. In human lung, PGE2 was observed to inhibit 
bronchoconstriction induced by allergen [122]. Furthermore, immune cells such as 
macrophages, mast cells, eosinophils, neutrophils and Th2 cells are inhibited by PGE2 [123-
127]. In addition to this, PGE2 has been found to support the production of suppressive factors 
such as IL-10 [128] and trombospondin [129] by dendritic cells. They also enhance the ability 
of dendritic cells to cause T cell expansion [130-132]. EP2 and EP4 mediated PGE2 signalling 
promotes the production of Th17 cells [133-136]. 
Leukotrienes (LT) are also a class of bioactive lipids derived from intracellular AA through 
LOX enzymes. The nuclear membrane AA initially binds to 5-lipooxygenase-activating 
protein (FLAP) which transfers AA to LOX enzyme producing an unstable LTA4 [137]. 
Further conversion of LTA4 is controlled based on the cell type, like in neutrophils, LTA4 
hydration by LTA4 hydrolase (LTA4H) converted it to LTB4 [138]. The action of LTC4 
synthase causes the conversion of LTA4 to LTC4 in mast cells [139]. The extracellular 
cleavage of LTC4 produces LTD4 and LTE4. LTD4 has a notable contribution in mediating 
bronchoconstriction during allergic conditions such as asthma [140].  
1.5 INTERACTION BETWEEN MAST CELLS AND ILC2 
Extensive pro- and anti-inflammatory roles of mast cells and ILC2 in health and diseases 
suggests possible interactions between them. The elucidation of their interactions and 
therefore their ultimate effect could potentially facilitate the understanding of various 
inflammatory conditions better. Efforts have been made in the field to figure out the means 
of communication between them and this part of the thesis will review important finding 
from such studies.  
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As discussed in the previous section, ILC2 mediate immune responses via type 2 cytokine 
production playing roles in inflammation, allergy and tissue repair. Murine lung ILC2 
isolated from wildtype, RAG2-/- and STAT6-/- animals when treated with cysteinyl 
leukotrienes (cysLTs), interact with their receptors on ILC2. This leukotriene-mediated 
activation of ILC2 leads to their production of type 2 cytokines [141]. ILC2 express 
leukotriene receptors cysLT1 and especially found to be increased in atopic subjects. A recent 
study investigated the role of cysteinyl leukotrienes on ILC2. The results from this study 
showed that LTE4 facilitated the migration and cytokine production of human ILC2 in vitro. 
Further they enhanced the action of known ILC2 activators – IL-25, IL-33, TSLP and PGD2. 
These effects were hindered by cysLT1 antagonist. Further, LTE4, in presence of IL-2, 
upregulated the expression of IL-25 and IL-33 receptors [142]. Mast cells have long known 
for their production of lipid mediators such as prostaglandins and leukotrienes following 
FceRI activation. This classic characteristic of mast cells suggests a possibility of their 
interaction with ILC2 via cysLTs. Further, prostaglandin-mediated mast cell-ILC2 
interaction through CRTH2 has been demonstrated. It was observed that ILC2 were activated 
upon treatment with PGD2 from human skin tissues [73]. Further follow-up study in mice 
lung tissues showed the critical role of CRTH2-PGD2 interaction in ILC2 activation and 
cytokine release. This kind of ILC2 activation via CRTH2 was found commonly in lung 
tissues in comparison with skin ILC2. Hence the production of the potent activator PGD2 by 
mast cell, resulted in the ILC2 activation and promotion of allergic reaction in lung [116].  
Recent studies showed that serine proteases generated by activated mast cells produced 
mature forms of IL-33 that had potent effects on ILC2. The effects of tryptase-mediated 
cleavage of IL-33 3-fold increase in action when compared to the full-length IL-33. The 
cleaved IL-33 therefore caused strong increase in ILC2 and eosinophil expansion in vivo and 
lead to the production of Th2 cytokines such as IL-5 and IL-13 by ILC2 [143]. 
Th9 cells promote lung inflammation mainly by the production of IL-9. Studies conducted in 
cystic fibrosis patient samples lead to the proposal of a positive feedback mechanism wherein 
the released IL-9 induced the IL-2 production by mast cells. The action of IL-2 lead to the 
activation of CD25+ ILC2 ultimately causing the increase in IL-9 production. In addition to 
IL-9, the cytokines released from the ILC2 activation during this loop contributed to the 
inflammatory reactions [144].  
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Figure 3: Interaction between mast cells and ILC2 
 
Yet another mast cell-ILC2 interaction pathway has been recently proposed in helminth 
infected mice models. Intestinal epithelial cells undergo apoptosis during helminth infection. 
The released ATP molecule induce mast cell degranulation and IL-33 release, which causes 
the activation of ILC2 that results in IL-13 production. This ILC2 activation pathway 
ultimately leads to goblet cell hyperplasia and the clearance of helminth infection [145].  
Continuous research carried out in the field could result in more interesting insights into the 
possible mast cell-ILC2 interaction mechanisms. These data consistently help in unravelling 
the role of these cells in health and diseases.  
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2 METHODS 
 
Patient sample collection 
All the studies included in this thesis were done on freshly obtained and processed human 
samples from surgeries. We value these samples a lot and preciously protect the interests of 
our donors.  
 
Lung 
Lung tissue samples used in papers I and II were obtained from the lung resection surgery of 
tumor patients at Karolinska University Hospital, Solna, Sweden. A portion of the lung tissue 
was cut out from the region far from tumor site. The obtained tissue was stored in Krebs-
henseleit buffer on ice until the beginning of tissue processing. It was taken into account that 
the patients did not receive chemotherapy or radiotherapy. The donors were provided with 
informed written consent and the study was approved by regional review board in Stockholm.  
 
Tonsil and Buffy coats 
Tonsil and blood samples were the main sources of immune cells used in papers III and IV. 
The tonsil tissues were obtained from the routine tonsillectomy operations conducted on 
patients with obstructive sleep and apnea syndrome at ear nose throat clinic, Karolinska 
University Hospital, Huddinge, Sweden. Blood samples were provided by the blood bank at 
Karolinska University Hospital, Huddinge. The use of such samples were used with proper 
consent from patients and the studies were approved by the regional ethical board at 
Karolinska University Hospital.  
 
Flow cytometric analyses and sorting 
Flow cytometric analyses and sorting is one of the main methods used in all the four studies 
included in this thesis. The technique enables the identification and distinguishing of various 
cell populations at once based on the different surface molecules they express. The isolated 
cells from the human tissue were incubated with antibodies that can bind to the surface 
molecules on the cells of our interest. Each of these antibodies are tagged with different 
flourochromes. The focus of papers I and II involved the efficient isolation and single cell 
sequencing of mast cells. The papers III and IV involved the sorting of ILC2, expanding them 
and analyzing these cells using flow cytometer. In order to perform this, mast cells, NK cells 
and ILCs were stained for their surface markers by incubating the cells under question in a 
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pool of fluorescently labelled antibodies that bound to the surface molecules on our desired 
cells. Thereafter, the cells were stained for live/dead markers to rule out the dead cells from 
analyses. Intracellular tryptase staining of mast cells was performed by permeabilization of 
cells followed by blocking step to rule out non-specific binding using blocking buffer 
consisting of 5% dry milk and 2% FCS in PBS. Cells were thereafter stained with Tryptase 
antibody conjugated with a flourochrome and then subjected to flowcytometric analyses. 
Similarly, intracellular cytokine staining of ILCs were performed by permeabilizing and then 
staining them with appropriate antibodies. The data obtained from the flow experiments were 
analyzed using the Flowjo software. 
 
Single cell RNA sequencing 
In paper II, single cell RNA sequencing was performed using Smart-seq2 that facilitated full-
length characterization of the entire transcriptome. The sequencing process was carried out 
by our collaborators from Science for life laboratory, Solna. A brief description of the entire 
process is presented in this section. The mast cells isolated from fresh lung tissue were sorted 
as single cells into 384 well plates using a flow cytometer. The lysis buffer contained free 
dNTPs and oligo-Dt primers necessary for cDNA synthesis. Once sorted, the single mast 
cells were lysed and the released RNA were converted to cDNA by reverse transcriptase 
enzyme. This enzyme acts by the addition of 2-5 nucleotides on the 5’ end of mRNA thus 
creating overhangs mostly composed of cytosine. A template switch oligo with the same 
anchor sequence as the oligo-dT at its 5’ facilitates the CDNA extension with template switch 
oligo as template. The template switch oligo contains special locked nucleic acid that 
increases the cytosine binding strength and thermal stability. The cDNA thus carries same 
known anchor sequencing facilitating the subsequent PCR reaction. The cDNA is randomly 
amplified with Tn5 transposase containing adaptor sequence. Finally, an enrichment PCR 
introduced unique adaptor sequences to be able to pool them and run on the same lane of 
Illumina sequencing instrument. 
 
Culture, expansion and treatments of mast cells and ILC2 
Freshly sorted ILC2 were cultured in IMDM media containing Yssel’s supplement, 1% 
serum, penicillin and streptomycin. The cells were expanded and maintained in culture for 
two weeks with irradiated PBMC and JY cells as feeders. The culture was done under the 
presence of IL-2, IL-4 and phytohemagglutinin. The cells were maintained in U bottom 96 
well plates for one week in 200ul media and then to a 24 well plate, where they were 
maintained as 1ml cultures. Media was changed once in every two days. In order to treat 
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them with different culture conditions, the maintained cells were seeded as 5x104 cells/well. 
Seeded cells were thereafter subjected treatment conditions depending on the aim of the 
experiment. For LC-MS, cells were seeded at a concentration of 2.5x105 and incubated for 
24 hours. Supernatants were collected following each experiment to assess the effects using 
ELISA. 
  
ELISA 
The effect of various treatment conditions was deciphered by measuring the type and 
theamount of cytokines released by the cells into the supernatant. This is done by ELISA, a 
sandwich immunoassay that detects the specific cytokine levels. IL-5 and IL-13 were 
detected by the commercially available Duo set kit from R&D systems and human IL-13 kit 
from Sanquin.  
 
RT-qPCR 
Total RNA was extracted from the tonsil cultures using RNeasy kit from Qiagen. cDNA 
synthesis was performed by using commercially available iScript cDNA synthesis kit. For 
PCR reactions, gene specific primers and SsoAdvancedTM Universal SYBR® Green 
supermix (Bio-Rad) were used. The reactions were performed on CFX Connect Real-Time 
PCR Detection System (Bio-Rad). 
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3 AIMS  
 
In this thesis, we set out to study mast cells and ILC2 and their role in type-2 immune 
responses in detail.  
 
Paper I – To optimize a protocol to efficiently isolate mast cells from human lung tissues. 
 
Paper II  – To study human lung mast cells on a single cell level using RNA sequencing 
platform. 
 
Paper III – To determine the production of PGD2 by human ILC2 and to investigate their 
endogenous effects on ILC2. 
 
Paper IV – To elucidate the role of PGE2 in human ILC2 regulation. 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I: AN OPTIMIZED PROTOCOL FOR THE ISOLATION AND 
FUNCTION ANALYSIS OF HUMAN LUNG MAST CELL 
The aim of this study was to optimize a protocol to isolate mast cells from human lung tissue 
by increasing yield and not sacrificing cell viability. Modern day techniques such as flow 
cytometry, RNA sequencing at single cell level can be used to study cells, including mast 
cells, on a highly detailed level. This will enable us to understand the biology of these cell 
types and unravel their physiological and pathophysiological roles. However, mast cell being 
a highly granular tissue-resident, it is necessary to optimize a protocol to facilitate their 
efficient isolation from complex tissues such as human lung. In this paper, we developed a 
protocol named WEMP – Washing, Enzymatic digestion, Mechanical disruption and Percoll 
purification, where each and every step is optimized to reduce cell death and significant 
increase the mast cell yield. During wash, red blood cells and blood pockets in the tissue are 
gently removed in order not to lose the immune cells (Paper I, Figure 1B-C, 1J-O) and to 
avoid treating final cell suspension with repeated ACK lysis buffer to lyse RBC, which can 
affect cell viability. Increasing enzymatic digestion time can increase total number of cells 
isolated. Enzymatic digestion with collagenase can affect cell surface marker, which is vital 
for fluorescence-based cell analyses. In this protocol, we however did not change enzymatic 
digestion time from conventional protocol (45 minutes). We instead included an additional 
step called mechanical disruption, where we collect enzymatically digested tissue pieces and 
use a 50ml syringe to mechanically disrupt it 10 times (repeated thrice) to squeeze out tissue-
resident cells such as mast cells (Paper I, Figure 1 S-U). This step will not only squeeze 
mast cell in particular but also other tissue-bound cells such as macrophages. Also, a 
conventional Percoll based mast cell purification by using 70%-30% Percoll interface might 
not be efficient to isolate all mast cells. Therefore, we re-suspended cells from mechanical 
disruption in 30% Percoll, centrifuged it and isolated all immune cells along with remaining 
RBCs. Using this Percoll gradient, larger alveolar macrophages will be collected in the 
supernatant along with cell debris (Paper I, Figure 1W). Cells are then washed and treated 
with ACK lysis buffer to get rid of RBC (Paper I, Figure 1X). Yield of human lung mast 
cell from WEMP protocol was significantly increased compared to conventional protocol 
(enzymatic digestion) (Paper I, Figure 3). We also isolated ILC2 and compared it with 
conventional protocol. Percentage of ILC2 of CD45 was similar between WEMP and 
conventional protocols. However, increase in total number of cells isolated using WEMP 
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protocol means that increase in total number of ILC2. This is important as ILC2 are known 
to be rare in number and in in vitro experiments using freshly isolated ILC2 and single cell 
sorting, such increase will be effective. Another application of WEMP protocol is isolation 
of all immune cells using 30% Percoll, which enables us to isolate all immune cells including 
lymphocytes and granulocytes. This is particularly helpful in studying different cell types at 
once, as we managed to do the flowcytometric analysis and sorting on lymphocytes and 
granulocytes using same FACS panel. Also, more cell numbers mean that cells from such a 
tissue can be used for different studies and scientific collaborations at same time. 
4.2 PAPER II:  DECIPHERING THE HETEROGENEITY OF HUMAN LUNG 
MAST CELLS BY SINGLE CELL RNA SEQUENCING 
The aim of this study was to characterize human lung mast cells on a more detailed level 
using single cell RNA sequencing platform. Human lung samples received post-surgery were 
processed using WEMP protocol as described in paper I. Using fluorescent-activated single 
cell sorting, mast cells, ILC and NK cells were sorted in 96 well plates containing lysis buffer 
(Paper II, Figure 1). Following the quality control analyses, sequencing of the sorted cell 
populations was carried out by SciLifeLab Eukaryotic Single-cell Genomics Facility, 
Stockholm, and delivered to 183 Uppmax c2016002. Principle component analyses of the 
sequencing data showed three different sorted populations – mast cells, ILC and NK cells. 
Further results of the analyses are summarized with a particular focus on mast cells as this is 
the aim of our study.  Primarily, the expression of key mast cell markers such as CD117/KIT, 
IgE receptor FceRI, IL-33 receptor IL1RL1, tryptase, chymase, carboxypeptidase, histidine 
carboxylase, prostaglandin synthase and arachidonate-5-lipoxygenase i.e., 5-lipoxygenase, 
were confirmed from the sequencing data, which as validates the single cell sort (Paper II, 
Figure 2A-2D). Key observation here was that not all mast cells expressed chymase. This 
data is cohesive with the fact that chymase is generally not expressed by mucosal mast cells 
[146].  
Following this, top 50 highly expressed genes were found that made up to 24% of totally 
gene expressed. Well studied mast cell markers observed among the highly expressed genes 
were tyrosine kinase receptor KIT, tryptase genes TPSAB1 and TPSAB2, IL-33 receptor and 
GATA2 transcription factor.  
We then set out to decipher the highly variable genes (HVG) within the sorted cell population 
as shown in the violin plots (paper II, Figure 3A). Elucidation of HVG expression remains 
as a basic aspect of this kind of studies as it helps us identify subpopulations within a cell 
type and therefore unravel their biological functions. Recognizing subsets within a cell 
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population and understanding their roles in vivo can serve as a basis for being able to 
specifically target them in various treatment strategies. Among the identified HVG from the 
sequencing data, cathepsin G and prostaglandin endoperoxide synthase 2 (PTGS2) were 
well-known mast cell markers [147, 148]. Cathepsin G has been shown to be generally 
expressed in the mast cell subset MCTC. PTGS2 is a main enzyme that catalyses prostaglandin 
biosynthesis. Dual specificity phosphatases (DUSP6) is a MAP kinase phosphatase that has 
main role in mast cell stimulation during PI3K pathway [149]. Among the other identified 
HVG were TSC22D1, ZNF331, CD83, MAOB, SGK1, SLC43A3.  
Hierarchical clustering of batch-corrected log- HVG expression were used to cluster them 
into putative sub-populations. This analysis did not indicate the presence of subpopulation. 
The results from t-SNE plots were also consistent with this.  
Top 50 abundant genes from the sequencing data was then looked at. Among them were 
RSG1 and RSG2 – regulators of mast cell signalling in inflammation, FOS – regulators of 
mast cell degranulation, SRGN – hematopoietic core glycoprotein critical in production and 
storage of mast cell proteases, HDC – histidine decarboxylase in histamine formation and 
thereby mediating allergic diseases. Preliminary pathway analyses based on the above 
observations was carried out using enricher. Gene expression profile noted from these results 
followed by pathway analysis confirmed the involvement of mast cells in TNF, PI3K and 
MAPK pathways.  
Such thorough in-depth studies form the basis for better understanding of mast cell functions 
and building a targeted approach for the development of new therapeutic strategies. 
4.3 PAPER III: CYTOKINE-INDUCED ENDOGENOUS PRODUCTION OF PGD2 
IS ESSENTIAL FOR HUMAN ILC2 ACTIVATION 
ILC2 have long been known to be activated by epithelial derived cytokines IL-33, IL-25 and 
TSLP to produced their signature type 2 cytokines IL-5 and IL-13[150]. Although ILC2 can 
be activated by each one of these epithelial cytokines individually, their synergistic effect 
leads to a very potent ILC2 activation [151]. This highly potent type 2 cytokine producing 
effect of ILC2 is not only significant in the induction of type 2 immune responses, but also 
in maintaining them during inflammatory conditions such as allergy and asthma[152]. In 
addition to the above mentioned epithelial derived cytokines, PGD2 was also shown to be 
important for ILC2 activation, chemotaxis and proliferation [73, 115, 116]. Therefore, in this 
study our aim was to determine the possibility of PGD production by human ILC2 and its 
role in activation, proliferation and regulation of ILC2 functions. 
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Cells suspensions isolated from tonsil tissue were used to sort ILC2 by FACS. Sorted ILC2s 
were expanded in Yssel’s medium in the presence of IL-2 and IL4. After 2 weeks of 
expansion, ILC2 phenotype was confirmed by flow cytometry analysis. 
Our first goal was to investigate the effect of COX1/2 inhibition in ILC2 activation. For this, 
ILC2 were pre-treated for 40 minutes with flurbiprofen, a COX1/2 inhibitor and incubated 
with IL-2, IL-33, IL-25 and TSLP. Type 2 cytokines, IL-5 and IL-13, production was 
observed in the presence of IL-33, IL-25 and TSLP (along with IL-2). No cytokine production 
was observed in non-stimulated condition (only IL-2). However, IL-5 and IL-13 production 
by ILC2 were shown to be inhibited following flurbiprofen pre-treatment. Both IL-5 and IL-
13 release and production per cell analysed through ELISA and intracellular flow cytometry 
respectively showed that COX1/2 is required for ILC2 activation. Also, transcription factor 
GATA3, previously shown to be important for ILC2 activation, was upregulated following 
IL-33, IL-25 and TSLP stimulation. However, COX1/2 inhibition reduced GATA3 
upregulation (Paper III Figure 1). Above data suggest COX1/2 blockade inhibited the 
prostaglandin production, which might be critical for ILC2 activation. 
To confirm and investigate further, supernatant from non-stimulated ILC2 cultures, cytokine 
stimulated ILC2 cultures in presence or absence of flurbiprofen pre-treatment were analysed 
by high sensitivity mass spectrometry. Results from this analysis revealed presence of PGD2 
and its metabolites PGJ2, delta-12-PGJ2 (D12-PGJ2) and 13, 14 dihydro-15-keto PGD2 in 
supernatants of cytokine stimulated ILC2. However, supernatant from non-stimulated ILC2 
did not contain lipid mediator and the flurbiprofen pre-treatment inhibited release of lipid 
mediators by cytokine stimulation (Paper III, Figure 2).  
 
Upon confirming endogenous production of PGD2 and its metabolites by ILC2, our next aim 
was to look into effect of endogenous PGD2 on ILC2 activation. To investigate this, we aimed 
at inhibiting PGD2 release by blocking HPGDS inhibitor (KMN698) and look at its effect in 
ILC2 activation. As expected, blocking HPGDS inhibited IL-5 and IL-13 release and also 
reduced the cytokine-induced CD25 expression (Paper III, Figure 4). In the next 
experiment, we used a selective CRTH2 antagonist (CAY10471) to block CRTH2 receptor. 
Expanded ILC2 were pre-treated with the CRTH2 antagonist for 20 minutes and stimulated 
with IL-33, IL-25 and TSLP. CRTH2 antagonist pre-treatment inhibited IL-5 and IL-13 
production by ILC2 (Paper III, Figure 5). Inhibition of IL-5 and IL-13 production from 
activated ILC2 by blocking COX2, HPGDS and CRTH2 suggests that endogenously 
produced PGD2 by ILC2 upon activation is required for GATA3 upregulation and ILC2 
activation.  
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It was previously shown that PGD2 produced by mast cell is important for ILC2 activation. 
In this study we showed that ILC2 can endogenously produce PGD2 and its metabolites upon 
activation. However, it is noteworthy that the amount of PGD2 produced from ILC2 is much 
less when compared to mast cells. This finding is crucial as CRTH2 blocking can be a potent 
therapeutic target for ILC2 inhibition. 
4.4 PAPER IV: PROSTAGLANDIN E2 SUPPRESSES IL-5 AND IL-13 
PRODUCTION IN HUMAN TONSIL ILC2 
In Paper IV, we investigate the effect of another prostaglandin, PGE2, in human ILC2 
function. Taken into account the abundance of PGE2 in lung tissue and the roles of ILC2 in 
asthma conditions, it is worthwhile to investigate the PGE2 effects on ILC2 [120, 121]. This 
hypothesis is also supported by the fact that PGE2 has suppressive effects on Th2 cells, 
macrophages, mast cells and neutrophils [123-127]. 
Similar to paper III, ILC2 were sorted from human tonsil tissue using flow cytometry-based 
sorting. These sorted ILC2 were expanded for 2 weeks in Yssel’s medium with IL-2, IL-4 
and irradiated feeder cells for 2 weeks. Phenotype of expanded ILC2s were confirmed by 
flow cytometric analysis. 
Expanded tonsil ILC2, in the presence of IL-2, were stimulated with IL-33, IL-25 and TSLP 
in presence or absence of PGE2. IL-33, IL-25 and TSLP combination resulted in IL15 and 
IL-13 release, which was analysed by ELISA. PGE2 (30nM) was shown to inhibit IL-5 and 
IL-13 release. However, PGE2 had no effect on ILC2 cell viability and cell proliferation after 
24 hours. Further intracellular IL-5 and IL-13 production in ILC2 were analysed by 
flowcytometry (Paper IV, Figure 1). These results confirmed PGE2 inhibitory effect of IL-
5 and IL-13 on per cell basis. 
As production of IL-5 and IL-13 was inhibited, it was interesting to measure the effect on 
transcription factor GATA3, which is required for ILC2s cytokine production. As already 
shown in other studies, high intracellular GATA3 protein expression was high in non-
stimulated ILC2 and this was increased by cytokine stimulation[69]. Intracellular GATA3 
expression was significantly lowered in presence of PGE2. CD25, a receptor for IL-2, is also 
important for ILC2 co-stimulation. CD25 expression was upregulated following 24-hour 
cytokine stimulation and presence of PGE2 was shown to significantly lower CD25 
expression (Paper IV, Figure 2A-C). 
From the above results, it is understood that PGE2 effect on GATA3 and CD25 expression 
are part of a mechanism supporting IL-5 and IL-13 production in ILC2. 
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Our next aim was to investigate long lasting effect of PGE2 on ILC2. To study this effect, we 
incubated the expanded ILC2 in the above-mentioned treatment conditions for 72 hours. 
Compared to 24-hour time point ILC2 produced higher amount of IL-5 and IL-13 after 72-
hour incubation period. This IL-5 and IL-13 production was significantly lowered in the 
presence of PGE2 after 72-hour time point (Paper IV, Figure 3A-B). Also, GATA3 
expression and CD25 expression were low in the presence of PGE2 at 72-hour time point. 
PGE2 effect on CD25 expression was much stronger at the 72-hour time point when 
compared to 24-hour time (Paper IV, Figure 2D-F). This raised the question on the long 
lasting PGE2 effect on ILC2 proliferation as IL-2-CD25 interaction is important for 
proliferation. To answer this question, we used cell proliferation assay – cell trace violet dye 
at 72-hour time point. 
Cells were loaded with dye before treatment condition, as cells divide fluorescence of dye in 
cells diluted depending on number of cell division undergone. Cytokine stimulation of ILC2 
induced cell proliferation, which also could be attributed to increase in IL-5 and IL-13 
production compared to 24-hour time point. However, we observed the inhibitory effect on 
ILC2 proliferation in presence of PGE2 and most of the cells failed to undergo second cycle 
cell division (Paper IV, Figure 2G-I). This further confirms that PGE2 effect on per cell 
basis in reducing GATA3 and CD25 expression in ILC2. 
Importantly, similar inhibitory effect of PGE2 was observed in freshly sorted ILC2 from 
tonsil and buffy coat. Microscopic image of 5-day treatment condition of freshly sorted 
Tonsil and buffy coat ILC2 showed lower number of cells in presence of PGE2. In addition 
to this, reduced CD25 expression of ILC2 in presence of PGE2 confirmed PGE2 effect in 
ILC2 proliferation (Paper IV, Figure 4). 
Next, we investigated the mode of action of PGE2. PGE2 is known to act through 4 of its E-
prostanoid (EP) receptors, EP1, EP2, EP3 and EP4. The EP2 and EP4 mRNA expression was 
observed in tonsil ILC2. These expression levels were significantly higher when compared 
to EP1 and EP3 mRNA expression. This result was consistent with the data obtained from 
single cell study[153] (Paper IV, Figure 5). 
To further investigate role of EP2 and EP4 receptors in ILC2, we pre-treated expanded cells 
with EP2 and EP4 antagonist for 20 mins. Following this, the cells were incubated with IL-
2, IL-33, IL-25 and TSLP. IL-5 and IL-13 levels in supernatant were analysed with ELISA 
at 24-hour time point. Partial suppression of IL-5 and IL-13 release was observed in presence 
of one of the EP receptor antagonists. This indeed proved that both EP receptor antagonist 
was necessary to completely reverse PGE2 suppressive effect, confirming the EP2 and EP4 
receptor mediated PGE2 effect on ILC2. Similar involvement of EP2 and EP4 receptor effect 
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was observed in intracellular IL-5 and IL-13 production, CD25, GATA3 expression and ILC2 
proliferation (Paper IV, Figure 6). 
Comprehensively, this study showed the negative regulation of ILC2 by PGE2 through EP2 
and EP4 receptors. Adding to this effect of PGE2 in IL-5 and IL-13 production, we also 
showed their inhibitory action on ILC2 proliferation. Hence, PGE2-EP2/EP4 interaction can 
be a potential therapeutic target in allergy and asthma.  
Future perspectives 
The functions of type 2 immune responses in health and diseases are still left to be fully 
explored. By studying the critical roles played by mast cells and ILC2 can deepen our current 
knowledge about such responses. The data obtained from such studies can serve as a basis 
for future research.  
In order to probe the mast cell biology and functions, we employed a up-to-date single cell 
RNA sequencing technique. The extensive information that could be obtained from such 
studies can potentially put us one step ahead in fully understanding mast cells. To be able to 
perform an effective sequencing reaction that could yield good quality data, it was crucial for 
us to isolate intact mast cells from complex tissues such as the lung. Application of the 
WEMP protocol in human lung tissue has facilitated this and thereafter, WEMP protocol can 
be further optimized for the isolating and studying mast cells from other relevant tissues. It 
would be of great value to extend the studies by having the mast cell sequencing data as the 
basis. The gene expression profile of mast cells from lung can be compared with that of the 
other tissues such as skin to understand their tissue-specific roles.  
ILC2 stand in need for various signals for their activation and regulation. ILC2 play 
significant roles in initiating and maintaining type 2 immune responses. Improved knowledge 
about the regulation of these cells is necessary for the development of novel therapeutics. 
Several studies are being conducted to study the lipid mediators and their effects on ILC2. 
The elucidation of the activating and suppressive action of two such lipid mediators, PGD2 
and PGE2, on ILC2 from human tissues will serve as a basis for further studies. Following 
the observations from these studies, it will be worthwhile to investigate the effects of various 
other lipid mediators on ILC2 and also to determine their long-term effect. The 
prostaglandins studied here can further be exploited as a therapeutic targets by CRTH2 
antagonist or EP2/4 agonist in treating inflammatory conditions due to their activating and 
suppressing effects.  
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